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MSC profile. (A), (D) and (E) Relative gene expression by N-(blue bars), TMSCs (red bars) and BM-MSCs (purple bars) assessed by qPCR and analyzed as a fold change in expression.
Graphs show the mean of triplicates ± SD. TBP (A and D) or GAPDH (E) were used as housekeeping genes. Statistical significance was determined by a multiple T-test, corrected for multiple comparisons using the HolmSidak method and the p-value for significance (* indicates significance at P < 0.05; **, P < 0.01; ns, not significant). 
Supplemental Experimental Procedures
Primary MSC isolation T-MSCs and N-MSCs were isolated after mechanical and enzymatic disruption of the fresh primary human tumor samples and adjacent macroscopically normal lung tissue (project authorization n°131/12), in IMDM (GIBCO) supplemented with collagenase II and IV (0.5 mg/ml, GIBCO) and DNAse I (0.1 mg/ml, Roche) for 2h at 37°C.
Multilineage differentiation potential of MSCs
MSC differentiation potential along osteocytic, chondrocytic and adipocytic lineages was assessed in culture using three different conditioned media. For induction of osteocytic and adipocytic differentiation, MSCs were seeded at 0.1 M cells/well in 12-well plates, in 1 ml medium/well. When MSCs reached 80% confluence, cells for osteocytic induction were treated with DMEM (GIBCO), supplemented with PS 1%, FCS 10%, NEAA 1%, APP (Ascorbic Acid P; 50 µg/ml, Sigma), Dexamethasone (10 -7 M, Sigma) and βGP (betaGlycerophospate; 5 mM, Sigma). For adipocytic differentiation, MSCs were treated with IMDM, supplemented with 1% PS, 10% FCS and 1% NEAA, ITSS (Insulin Transferin Sodium Selenite; 10 µg/ml, Roche), Dexamethasone (10 -6 M), Indometacine (100 µM, Fluka) and IBMX (3 Isobutyl 1 Methylxanthine, 100 µM, Sigma). Control conditions for both inductions are MSCs cultured in MSC medium. For chondrocytic induction, MSCs were cultured as a pellet at 0.5 M cells/pellet, in 1ml medium. Induction medium was composed of DMEM (high glucose), 1% PS, ITSS (10 µg/ml) and linoleic acid (1 mg/ml, Sigma), with AAP (50 µg/ml), Dexamethasone (10 -7 M), and TGFβ (10 ng/ml, Miltenyi Biotec). Control medium consisted of DMEM, 1% PS, ITSS (10 µg/ml) and linoleic acid (1 mg/ml). Following the treatments, cells were fixed and stained with oil red O (adipocytes), silver nitrate for von Kossa staining (osteocytes), and Alcian blue (chondrocytes).
Immunohistochemistry (IHC)
T-and N-MSCs grown in 24-well plates (40,000 cells/well) for 24 hours were washed twice in PBS, then were fixed at room temperature in 4% PFA, and were stained with anti-vimentin (#M0725, Dako) and anti-α-SMA (#ab5694, Abcam) antibodies.
Characterization of tumor-infiltrating immune cells by IHC
Whole-tissue sections from the SCC were formalin-fixed and paraffin-embedded (FFPE) and stained with antibodies to assess immune cell infiltration. Haematoxylin/eosin staining (J.T. Baker; Merk) and staining with anti-CD3 (2GV6, #790-4341, Roche), -CD20 (#CD20-L26-L-CE, Novocastra), -CD68 KP1 (#GA60961-2, DAKO), -PD-L1 (#SP263, Roche Ventana), -Granzyme B (GrB-7, #MON7029-1, MONOSAN), -CD56 (#NCL-L-CD56-1B6, Novocastra), -CD8 (C8/144B, #MA5-13473, DAKO), -PD1 (#AF1086, R&D), -CD4 (SP35, #790-4423, Ventana), -FoxP3 (236A/E7, #ab20034, Abcam) antibodies were performed.
Flow Cytometry
For all experiments, cells were first incubated 15 minutes with FcR Blocking Reagent (Miltenyi), and then stained for 30 min with conjugated antibodies at 4°C. Before acquisition, cells were washed in PBS and fixed in 1% PFA. All samples were acquired with a Gallios Cytometer (Beckman Coulter) and data analyzed using FlowJo version10 software. The initial gating strategy included cell size selection, cell doublet and dead cell exclusion (with fixable viability dye (LIVE/DEAD®, #L-34963, Life Technology) or DAPI). Beads were used to set compensation for multicolor flow cytometry experiments (VersaComp Antibody Capture Bead kit, #22804, Beckman Coulter). 
